# Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer

> **NCT05580445** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shouyao Holdings (Beijing) Co. LTD** · enrollment: 114 (estimated)

## Conditions studied

- Advanced Pancreatic Cancer

## Interventions

- **DRUG:** CT-707
- **DRUG:** Toripalimab
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT05580445
- **Lead sponsor:** Shouyao Holdings (Beijing) Co. LTD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-11
- **Primary completion:** 2024-08-11
- **Final completion:** 2024-08-11
- **Target enrollment:** 114 (ESTIMATED)
- **Last updated:** 2023-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05580445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05580445, "Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05580445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*